Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies
出版年份 2015 全文链接
标题
Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies
作者
关键词
Pharmacokinetic Parameter, Lean Body Mass, Population Pharmacokinetic Model, Visual Predictive Check, Transit Compartment
出版物
CLINICAL PHARMACOKINETICS
Volume 55, Issue 3, Pages 397-405
出版商
Springer Nature
发表日期
2015-09-04
DOI
10.1007/s40262-015-0327-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
- (2015) M. Boi et al. CLINICAL CANCER RESEARCH
- Abstract LB-231: A phase I pharmacokinetic study of OTX015 for the treatment of patients with hematologic malignancies
- (2015) Elodie Odore et al. CANCER RESEARCH
- Abstract 5531: OTX015, a novel BET inhibitor, is a promising anticancer agent for multiple myeloma
- (2015) Maria Todaro et al. CANCER RESEARCH
- Development and validation of an UPLC-MS/MS method for quantitative analysis of OTX015 in human plasma samples
- (2014) Elodie Odore et al. Analytical Methods
- 5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies
- (2014) A. Stathis et al. EUROPEAN JOURNAL OF CANCER
- Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients
- (2014) Quentin Chalret du Rieu et al. INVESTIGATIONAL NEW DRUGS
- Abstract C244: Development of the BET bromodomain inhibitor OTX015.
- (2014) J. K. Noel et al. MOLECULAR CANCER THERAPEUTICS
- A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies
- (2014) K Althoff et al. ONCOGENE
- Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer
- (2013) T. Shimamura et al. CLINICAL CANCER RESEARCH
- Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
- (2013) Z. Cheng et al. CLINICAL CANCER RESEARCH
- BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
- (2012) C. J. Ott et al. BLOOD
- Down-regulation of NF-κB Transcriptional Activity in HIV-associated Kidney Disease by BRD4 Inhibition
- (2012) Guangtao Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search